Ensysce Biosciences (ENSC) Return on Capital Employed (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Return on Capital Employed of 532.54% for Q3 2025, down 34068.0% year-over-year from N/an in Q3 2024, and down 106.63% quarter-over-quarter from 257.73% in Q2 2025.
Ensysce Biosciences (ENSC) Return on Capital Employed (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Return on Capital Employed for 8 consecutive years, with 532.54% the latest figure, recorded in Q3 2025.
- In Q3 2025, Return on Capital Employed fell 34068.0% year-over-year to 532.54%; the TTM figure through Sep 2025 stood at 532.54% (down 34068.0% YoY), while the FY2024 annual figure was 345.94%, up 76636.0% from the prior year.
- Return on Capital Employed declined to 532.54% in Q3 2025 per ENSC's latest filing, from 257.73% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 2900.11% in Q4 2023 and bottomed at 2378.87% in Q1 2023.
- Historically, Return on Capital Employed has averaged 146.87% across 5 years, with a median of 205.02% in 2025.
- On a YoY basis, Return on Capital Employed climbed as much as 193542 bps in 2024 and fell as far as 302748 bps in 2024.
- Ensysce Biosciences' Return on Capital Employed stood at 256.26% in 2021, then surged by 298 bps to 1019.12% in 2022, then surged by 185 bps to 2900.11% in 2023, then tumbled by 104 bps to 127.37% in 2024, then plunged by 318 bps to 532.54% in 2025.
- Business Quant data shows ENSC's Return on Capital Employed at 532.54% in Q3 2025, 257.73% in Q2 2025, and 205.02% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -532.54% |
| Jun 30, 2025 | -257.73% |
| Mar 31, 2025 | -205.02% |
| Dec 31, 2024 | -127.37% |
| Sep 30, 2024 | -191.87% |
| Jun 30, 2024 | -367.59% |
| Mar 31, 2024 | -443.45% |
| Dec 31, 2023 | 2,900.11% |
| Sep 30, 2023 | -499.10% |
| Jun 30, 2023 | -657.45% |
| Mar 31, 2023 | -2,378.87% |
| Dec 31, 2022 | 1,019.12% |
| Sep 30, 2022 | 528.37% |
| Jun 30, 2022 | -1,608.53% |
| Mar 31, 2022 | -431.09% |
| Dec 31, 2021 | 256.26% |
| Sep 30, 2021 | 317.27% |
| Jun 30, 2021 | -81.28% |
| Mar 31, 2021 | -29.67% |
| Dec 31, 2020 | 1,199.20% |